Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Inventiva S.A.NASDAQ: IVA
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income grows 30.9% year over year
Q4 FY2025 net income of €176.94M (cash outflow) rose 30.9% year over year. Over 3 fiscal years it compounded at +84.4% a year.
Context
- Net income amounted to 7587.8% of revenue in FY2025, up 5585.1 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -€135.71M (-60.1%) for the fiscal year ending Dec 2026, a slowdown from the +84.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -€176.94M— QoQ
- Last fiscal yearDec 2025
- -€340.16M+84.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.9% | — | — |
| 1 year | +84.7% | -60.1% | -144.8 pp |
| 3-year CAGR | +84.4% | -45.0% | -129.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (340.16M) EUR
- Year-over-year change
- -84.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (340.16M) | -84.7% |
| FY2024 | 2024-12-31 | (184.21M) | -66.8% |
| FY2023 | 2023-12-31 | (110.43M) | -103.5% |
| FY2022 | 2022-12-31 | (54.27M) | -9.3% |
| FY2021 | 2021-12-31 | (49.64M) | — |
Net Income vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +84.7% is the 2nd highest of 10, against a peer median of -17.6%.
- Net income amounts to 7587.8% of revenue for IVA, versus a peer median of 1189.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Mar 2026 | $151.77M USD | +296.2% | — | 8550.6% | |
| LTM Mar 2026 | $133.22M USD | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $83.01M USD | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $77.6M USD | -45.6% | -39.9% | 138.9% | |
| LTM Mar 2026 | $61.98M USD | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M USD | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $54.64M USD | -17.6% | +16.2% | 167.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M USD | +84.6% | +27.3% | — |
| Peer median (excluding IVA) | — | -17.6% | +7.4% | 1189.1% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Depreciation & Amortization | (1.29M) | 1.7M | 2.6M | 5.2M | 3.22M |
| Deferred Income Tax | (3.27M) | (5.26M) | (4.74M) | (4.8M) | (2.3M) |
| Stock-Based Compensation | 2.09M | 2.22M | 3.97M | 3.58M | 26.77M |
| Change in Working Capital | 979K | 5.71M | 17.31M | 1.68M | 6.42M |
| Accounts Receivables | (5.32M) | 3.84M | (5.84M) | 2.81M | 816.45K |
| Inventory | (72K) | 19K | (44K) | 417K | 0 |
| Accounts Payables | 7.6M | 3.54M | 20M | 0 | 2.46M |
| Other Working Capital | (1.23M) | (1.69M) | 3.19M | (1.54M) | 3.15M |
| Other Non-Cash Items | 3.5M | 4.98M | 9.68M | 92.63M | 205.07M |
| Operating Cash Flow | (47.63M) | (44.93M) | (81.61M) | (85.93M) | (100.98M) |
| Capital Expenditures | (534K) | (561K) | (540K) | (333K) | (237.26K) |
| Acquisitions (Net) | 89K | 41K | 0 | 0 | 0 |
| Purchases of Investments | (1.35M) | (1K) | (8.3M) | 0 | (127.69M) |
| Sales of Investments | (89K) | 9.39M | 978K | 9.08M | 0 |
| Other Investing Activities | 90K | 1K | 131K | 75.72K | (1K) |
| Investing Cash Flow | (1.79M) | 8.87M | (7.73M) | 8.75M | (127.93M) |
| Debt Repayment | (28K) | 28.44M | (4.1M) | 19.92M | (5.98M) |
| Common Stock Issued | 25.48M | 8.83M | 28.08M | 57.34M | 237.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (17.73K) | (772.47K) | 5.1M | 68.33M | 236.98K |
| Financing Cash Flow | 25.45M | 37.27M | 29.08M | 145.59M | 232M |
| Effect of Forex Changes | 4.84M | (1.03M) | 445K | 1.24M | 11.08M |
| Net Change in Cash | (19.13M) | 183K | (59.82M) | 69.65M | 14.17M |
| Free Cash Flow | (48.16M) | (45.49M) | (82.15M) | (86.26M) | (101.22M) |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.